These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38824477)
21. Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression. Rong W; Wan N; Zheng X; Shi G; Jiang C; Pan K; Gao M; Yin Z; Gao ZJ; Zhang J Phytomedicine; 2022 Jan; 95():153867. PubMed ID: 34923234 [TBL] [Abstract][Full Text] [Related]
22. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D. Wang Y; Cao K J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695 [TBL] [Abstract][Full Text] [Related]
23. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305 [TBL] [Abstract][Full Text] [Related]
24. Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma. Kang J; Zheng Z; Li X; Huang T; Rong D; Liu X; Qin M; Wang Y; Kong X; Song J; Lv C; Pan X Cancer Cell Int; 2022 Oct; 22(1):312. PubMed ID: 36224624 [TBL] [Abstract][Full Text] [Related]
25. GRP78 Promotes Hepatocellular Carcinoma proliferation by increasing FAT10 expression through the NF-κB pathway. Luo C; Xiong H; Chen L; Liu X; Zou S; Guan J; Wang K Exp Cell Res; 2018 Apr; 365(1):1-11. PubMed ID: 29458176 [TBL] [Abstract][Full Text] [Related]
26. As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3β pathway. Liu L; Dong Z; Liang J; Cao C; Sun J; Ding Y; Wu D Oncogene; 2014 Feb; 33(7):909-20. PubMed ID: 23812429 [TBL] [Abstract][Full Text] [Related]
27. Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment. Zhang F; Hu K; Liu W; Quan B; Li M; Lu S; Chen R; Ren Z; Yin X Cell Mol Gastroenterol Hepatol; 2023; 15(3):573-591. PubMed ID: 36513250 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800 [TBL] [Abstract][Full Text] [Related]
29. GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. Yan J; Zhou B; Guo L; Chen Z; Zhang B; Liu S; Zhang W; Yu M; Xu Y; Xiao Y; Zhou J; Fan J; Li H; Ye Q Am J Cancer Res; 2020; 10(11):3705-3720. PubMed ID: 33294262 [TBL] [Abstract][Full Text] [Related]
30. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887 [TBL] [Abstract][Full Text] [Related]
31. FAT10 promotes hepatocellular carcinoma (HCC) carcinogenesis by mediating P53 degradation and acts as a prognostic indicator of HCC. Zhang Y; Zuo Z; Liu B; Yang P; Wu J; Han L; Han T; Chen T J Gastrointest Oncol; 2021 Aug; 12(4):1823-1837. PubMed ID: 34532131 [TBL] [Abstract][Full Text] [Related]
32. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885 [TBL] [Abstract][Full Text] [Related]
33. Acesulfame potassium upregulates PD-L1 in HCC cells by attenuating autophagic degradation. Kim DH; Kwon EJ; Park KG; Jin J; Byun JK Biochem Biophys Res Commun; 2024 Jun; 711():149921. PubMed ID: 38603831 [TBL] [Abstract][Full Text] [Related]
34. TREM2 Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359 [TBL] [Abstract][Full Text] [Related]
35. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression. Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468 [TBL] [Abstract][Full Text] [Related]
36. Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma. Chun HW; Hong R Oncol Lett; 2019 Jun; 17(6):5487-5498. PubMed ID: 31186768 [TBL] [Abstract][Full Text] [Related]